Advertisement

U.S. markets open in 6 hours 35 minutes

S&P Futures
4,487.00
+9.50(+0.21%)
Dow Futures
35,187.00
+54.00(+0.15%)
Nasdaq Futures
15,322.75
+32.25(+0.21%)
Russell 2000 Futures
2,267.90
+3.20(+0.14%)
Crude Oil
83.02
+0.58(+0.70%)
Gold
1,779.00
+13.30(+0.75%)

Advertisement

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

104.02-0.52 (-0.50%)

At close: 4:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Triple Moving Average Crossover

View all chart patterns

Performance Outlook

Previous Close	104.54
Open	104.47
Bid	0.00 x 800
Ask	0.00 x 1400
Day's Range	102.93 - 104.95
52 Week Range	84.77 - 120.27
Volume	429,656
Avg. Volume	621,378

Market Cap	9.845B
Beta (5Y Monthly)	0.72
PE Ratio (TTM)	27.99
EPS (TTM)	3.72
Earnings Date	Nov 01, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	Dec 29, 1995
1y Target Est	122.76

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-8% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NBIX

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Neurocrine Biosciences, Inc.
HALO: Lowering target price to $39.00HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $39.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
Rating
Fair Value
Economic Moat
6 days agoArgus Research

All

News

Press Releases

Research Reports

Insider Monkey
Hedge Funds Are Coming Back To Neurocrine Biosciences, Inc. (NBIX)
Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
- Hedge Funds Are Cashing Out Of Campbell Soup Company (CPB)
  Insider Monkey
- Where Do Hedge Funds Stand On IAA, Inc. (IAA)?
  Insider Monkey
PR Newswire
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 2021 Virtual Annual Meeting being held October 17–19, 2021.
- BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
  GlobeNewswire
- Global Chronic Rhinosinusitis Pipeline Report 2021 - ResearchAndMarkets.com
  Business Wire
Benzinga
Notable Neurocrine Biosciences Insider Trades $1.1M In Company Stock
Dimitri Grigoriadis, Chief Research Officer at Neurocrine Biosciences (NASDAQ:NBIX), made a large buy and sell of company shares on October 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Dimitri Grigoriadis exercised options to purchase 5,000 Neurocrine Biosciences shares at a price of $43.24 per share for a total of $216,200 on October 7. They then sold their shares on the same day in the open market. They sold at pr